NEWS
  • April 5, 2016 MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder
  • February 19, 2016 Pharmaceutical Processing | In Development: HSDD Treatment for Women
  • February 19, 2016 PM360 | Will Lorexys Succeed Where Addyi Flopped?
  • December 8, 2015 S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women
  • November 18, 2015 Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference
  • November 18, 2015 Dr. Robert Pyke from S1 Biopharma to Present at ExL Pharma CNS Clinical Trial Forum
  • June 5, 2015 S1 Biopharma Supports FDA Advisory Committee’s Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
  • March 3, 2014 S1 Biopharma prepares to initiate Phase 2a Clinical Trial for Low Male Sexual Desire
  • August 19, 2013 The Scientist | Opinion: Sexual Dysfunction Matters
S1 Biopharma
  • COMPANY
    • ABOUT US
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • MEDICAL ADVISORY BOARD
    • SOCIAL MEDIA COMMUNITY GUIDELINES
  • PIPELINE
    • LOREXYS
    • OREXA
    • S1B-307
    • S1B-3006
  • R&D
    • SEXUAL DYSFUNCTION
      • HSDD in Women
      • HSDD in Men
      • Arousal Disorder and Orgasmic Disorder
    • CLINICAL TRIALS
      • Lorexys 1000 Study
      • Orexa Study
    • MEDICAL AFFAIRS
    • SCIENTIFIC PUBLICATIONS
    • PARTNERING
  • NEWSROOM
    • PRESS RELEASES
    • MEDIA COVERAGE
  • INVESTORS
    • LOGIN
  • CONTACT US

MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder

April 5, 2016

Pharmaceutical Processing | In Development: HSDD Treatment for Women

February 19, 2016

PM360 | Will Lorexys Succeed Where Addyi Flopped?

February 19, 2016

S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women

December 8, 2015

Deal advances S1 Biopharma strategy for global commercialization of Lorexys. NEW YORK, Dec. 8, 2015 /PRNewswire/ — S1 Biopharma, Inc. a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women…

Read more ›

Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference

November 18, 2015

Mr. Sitchon will present an update on S1 Biopharma’s clinical stage development programs targeting treatment of diminished sexual desire in women and men. NEW YORK, Nov. 2, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for…

Read more ›

Dr. Robert Pyke from S1 Biopharma to Present at ExL Pharma CNS Clinical Trial Forum

November 18, 2015

Expert on female sexual dysfunction disorder and CNS drug safety to outline challenges in development of combination therapies for CNS disorders. NEW YORK, Oct. 31, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for the treatment of sexual…

Read more ›

S1 Biopharma Supports FDA Advisory Committee’s Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder

June 5, 2015

NEW YORK, June 5, 2015 /PRNewswire/ — Yesterday’s FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women’s health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD.…

Read more ›

S1 Biopharma prepares to initiate Phase 2a Clinical Trial for Low Male Sexual Desire

March 3, 2014

JERSEY CITY, N.J., March 3, 2014 /PRNewswire/ — S1 Biopharma today announced its plan to initiate Phase 2a clinical trials in the third quarter of this year for Orexa (S1P-205), its first-in-class therapy to treat male Hypoactive Sexual Desire Disorder…

Read more ›

The Scientist | Opinion: Sexual Dysfunction Matters

August 19, 2013

Financial Times | S1 Biopharma starts trial of female libido drug

July 29, 2013
‹ Older posts

  • CONTACT US
  • SITE MAP
  • Terms of Use
  • © S1 biopharma Inc.
S1 Biopharma, Inc.
7 World Trade Center
250 Greenwich St.
46th Floor
New York City, NY 10007
Email: info@s1biopharma.com